Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

BMYCelgeneRunning, no new patients

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

3Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 2 insiders sold shares within a month

    Since Sep 9, 2026 · was worth 5, fading over time

    +2.6
Worry score3

Score over time

Stage
Phase 1/2
Patients
130 (final count)
Started
Jun 3, 2016
Main results expected
Aug 2, 2018
Fully finished
Sep 30, 2026
Results posted
Nov 22, 2022

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)

    Measured over: From first dose to 28 days after first dose

  • The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)

    Measured over: From first dose to 28 days after last dose (up to approximately 13 months)

  • Overall Response Rate: Phase 2 (Randomized Stage)

    Measured over: From first dose up to approximately 26 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT02677922 · record last updated 2026-02-19 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02677922) ↗